ALERT!

This site is not optimized for Internet Explorer 8 (or older).

Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.

Journal and News Scan

Source: News from around the web.
Author(s): Claire Vernon

Patient Care and General Interest

A charity bazaar raised money for a Shanghai Chest Hospital project that offers free heart surgery to children with congenital heart disease in China.

Trillium Health Partners and Saint Elizabeth Health Care in Ontario, Canada, have been recognized with the Canadian College of Health Care Leader’s 3M Health Care Quality Team Award for their Putting Patients at the Heart Program, which focuses on postoperative care for cardiac patients.

 

Drugs and Devices

AtriCure and Baheal Pharmaceutical Group have agreed to a partnership for the latter to distribute AtriCure’s surgical ablation devices in China.

 

Research, Trials, and Funding

Survival after congenital heart surgery is improving; however, researchers from Minnesota, USA, find that mortality for this group of patients remains higher than in the general population, even for relatively mild structural defects.

Researchers from Ontario, Canada, find lower survival and higher likelihood of readmission for heart failure in patients who required a permanent pacemaker after transcatheter aortic valve replacement compared to patients who did not need a pacemaker.

Analysis of the Framingham Heart Study cohorts suggests that quitting smoking substantially lowers lung cancer risk, even within five years of quitting, although the risk for former smokers remains higher than for never-smokers.

Source: The Annals of Thoracic Surgery
Author(s): Lily E. Johnston, Emily A. Downs, Robert Hawkins, Mohammed Quader, Alan Speir, Jeff Rich, Leora Yarboro, Gorav Ailawadi

Johnston and colleagues evaluated morbidity and mortality following different cardiac operations at 18 institutions to determine if outcomes of coronary artery bypass grafting (CABG), aortic valve replacement, and mitral valve replacement were correlated within each institution. The large volume of CABG makes this procedure an obvious choice for large-scale measurement and reporting of outcomes, and the authors sought to determine if CABG outcomes correlated with, and could therefore be considered representative of, valve replacement outcomes. While the institutional observed-to-expected (OE) ratios for mortality were not correlated across the three procedures, the OE ratios for morbidity were. The authors suggest this could reflect greater dependence of morbidity on postoperative care and resources that are more broadly shared within an institution and greater dependence of early mortality on procedure-specific skills.

Source: European Journal of Cardio-Thoracic Surgery
Author(s): Monica Dobrovie, Ricardo A Spampinato, Elena Efimova, Jaqueline G da Rocha e Silva, Julia Fischer, Michael Kuehl, Jens-Uwe Voigt, Ann Belmans, Agnieszka Ciarka, Fernanda Bonamigo Thome Valerie Schloma, Yaroslava Dmitrieva, Sven Lehmann, Jochen Hahn, Elfriede Strotdrees, Friedrich-Wilhelm Mohr, Jens Garbade, Anna L Meyer

Dobrovie and colleagues performed a retrospective analysis of mitral regurgitation (MR) in 128 patients who had a left ventricular assist device (LVAD) implanted. The authors found that even severe MR improved following LVAD implantation without intraoperative repair of the valve. Survival after one and three years for patients with severe preoperative MR was comparable to LVAD patients with none to moderate preoperative MR.

Source: Annals of Cardiothoracic Surgery
Author(s): Simone T. Timman, Christiana Schoemaker, Wilson W. L. Li, Henri A. M. Marres, Jimmie Honings, Wim J. Morshuis, Erik H. F. M. van der Heijden, Ad F. T. M. Verhagen

Timman and colleagues assessed the functional outcomes of patients who underwent laryngotracheal resection (LTR) and reconstruction for benign laryngotracheal stenosis. Between 1996 and 2017, 119 consecutive patients underwent LTR (n = 47) or end-to-end segmented tracheal resection (n = 56). There was consistent functional improvement during follow-up, particularly with respect to the sensation of dyspnea during exercise and the reduction of inspiratory stridor, although early voice alterations without recurrent nerve palsy were reported more often after LTR (34% versus 16%). All airway-related scores and quality of life measures improved significantly following both therapeutic modalities. While these results are promising, the low questionnaire response rate (63%) prompts caution.

Source: European Journal of Cardio-Thoracic Surgery
Author(s): Stuart W Grant, Gary S Collins, Samer AM Nashef

Risk-prediction models are well-known in cardiac surgery—the EuroSCORE and STS models being some of the most recognized. They are used for risk stratification, decision-making, and benchmarking. However, development of these models can be complex and once a model is developed, it is important to validate it. This article by Grant and colleagues discusses various issues in developing and validating risk-prediction models to aid clinicians in gaining a basic understanding of the advantages and limitations of such models.

Source: News from around the web.
Author(s): Claire Vernon

Patient Care and General Interest

World No Tobacco Day was observed on May 31st, and it focused on cardiovascular disease with the 2018 theme of “Tobacco breaks hearts. Choose health, not tobacco.”

The US Food and Drug Administration recently released a safety communication focusing on surgical fires and practices that can prevent them.

Experts in India campaign for mandatory screening of newborns for critical congenital heart disease.

 

Research, Trials, and Funding

A surgeon in California shared his experience with awake video-assisted thoracic surgery at the recent Annual Meeting of the American Thoracic Society.

Early results suggest good 30-day outcomes with the Tendyne Transcatheter Mitral Valve Replacement system from Abbott, say researchers from Sydney, Australia, who presented the results at the recent EuroPCR meeting in Paris, France.

Source: European Journal of Cardio-Thoracic Surgery
Author(s): Sang Yoon Kim, Suryeun Chung, Dong Jung Kim, Jun Sung Kim, Cheong Lim, Kay-Hyun Park

Kim and colleagues retrospectively analyzed long-term patency of reimplanted branch vessels following thoracoabdominal aortic aneurysm repair in 168 patients. Patency rates were high for visceral branches. For segmental arteries, patency rates depended on reimplantation technique and were worst for graft interpositions.

Source: The New England Journal of Medicine
Author(s): Matthew D. Hellmann, Tudor-Eliade Ciuleanu, Adam Pluzanski, Jong Seok Lee, Gregory A. Otterson, Clarisse Audigier-Valette, Elisa Minenza, Helena Linardou, Sjaak Burgers, Pamela Salman, Hossein Borghaei, Suresh S. Ramalingam, Julie Brahmer, Martin Reck, Kenneth J. O’Byrne, William J. Geese, George Green, Han Chang, Joseph Szustakowski, Prabhu Bhagavatheeswaran, Diane Healey, Yali Fu, Faith Nathan, Luis Paz-Ares

This randomized trial evaluating the relative efficacy of immunotherapy and chemotherapy in patients with recurrent or metastatic disease, immunotherapy was associated with significantly better progression-free survival.  Tumor mutational burden was a marker for patient selection for immunotherapy.

Source: The Annals of Thoracic Surgery
Author(s): Rong Liufu, Guocheng Shi, Fang Zhu, Yongmei Guan, Zhaohui Lu, Weimin Chen, Zhongqun Zhu, Huiwen Chen

Liufu and colleagues evaluated outcomes for repair of supracardiac total anomalous pulmonary venous connection via the superior approach in 198 pediatric patients, with a median age of 95 days at the time of surgery. Repair via the superior approach avoids dispensable incisions to the atrial septum, extra force being placed on the heart, and potential anastomotic distortion. The authors found that rates of both survival (97%) and freedom from postoperative pulmonary venous obstruction (85%) were acceptable using this approach.

Source: The New England Journal of Medicine
Author(s): Leena Gandhi, Delvys Rodríguez-Abreu, Shirish Gadgeel, Emilio Esteban, Enriqueta Felip, Flávia De Angelis, Manuel Domine, Philip Clingan, Maximilian J. Hochmair, Steven F. Powell, Susanna Y.-S. Cheng, Helge G. Bischoff, Nir Peled, Francesco Grossi, Ross R. Jennens, Martin Reck, Rina Hui, Edward B. Garon, Michael Boyer, Belén Rubio-Viqueira, Silvia Novello, Takayasu Kurata, Jhanelle E. Gray, John Vida, Ziwen Wei, Jing Yang, Harry Raftopoulos, Catherine Pietanza, Marina C. Garassino, for the KEYNOTE-189 Investigators

The addition of pembrolizumab (targeting PD-1) to standard chemotherapy substantially improved time to progression and overall survival compared to chemotherapy alone in patients with metastatic lung cancer.

Pages